Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma
- PMID: 28784103
- PMCID: PMC5547483
- DOI: 10.1186/s12885-017-3521-0
Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma
Abstract
Background: Bleomycin-induced lung injury, a major complication of chemotherapy for germ cell tumors, occasionally fails to respond to the standard treatment with corticosteroids and develops into severe respiratory insufficiency. Little is known about salvage treatment for refractory cases.
Case presentation: A 63-year-old man who had been diagnosed with stage I seminoma and undergone a high orchiectomy 1 year previously developed swelling of his left iliac lymph node and was diagnosed with a recurrence of the seminoma. He was administered a standard chemotherapy regimen of cisplatin, etoposide, and bleomycin. At the end of second cycle, he developed a dry cough and fever that was accompanied by newly-identified bilateral infiltrates on chest X-ray. Despite initiation of oral prednisolone, his exertional dyspnea and decline in pulmonary functions continued to be aggravated. High-dose pulse treatment with methylprednisolone was introduced and improved his symptoms and radiologic findings. However, the maintenance dose of oral prednisolone allowed reactivation of the disease with evidence of newly-developed bilateral lung opacities on high-resolution CT scans. Considering his glucose intolerance and cataracts as complications of corticosteroid treatment, administration of pirfenidone was initiated with the patient's consent. Pirfenidone at 1800 mg/day was well tolerated, and resolved his symptoms and abnormal opacities on a chest CT scan. Subsequently, the dose of prednisolone was gradually tapered without worsening of the disease. At the most recent follow-up, he was still in complete remission of seminoma with a successfully tapered combination dose of prednisolone and pirfenidone.
Conclusions: Pirfenidone, a novel oral agent with anti-inflammatory and -fibrotic properties, should be considered as a salvage drug for refractory cases of bleomycin-induced lung injury.
Keywords: Anti-fibrotic agent; Bleomycin; Lung toxicity; Pirfenidone; Refractory.
Conflict of interest statement
Ethics approval and consent to participate
The study was approved by the Institutional Review Committee of Nagoya University Hospital (approval number 44).
Consent for publication
Written consent for publication of the case was obtained from the patient.
Competing interests
The authors have no competing interest, including relevant financial interests, activities, and affiliations.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures

Similar articles
-
Combined prednisolone and pirfenidone in bleomycin-induced lung disease.J Cancer Res Ther. 2016 Jul-Sep;12(3):1198-1202. doi: 10.4103/0973-1482.197530. J Cancer Res Ther. 2016. PMID: 28054535
-
Bleomycin-induced pneumonitis in three patients treated with chemotherapy for primary advanced seminoma.J BUON. 2015 May-Jun;20(3):928-32. J BUON. 2015. PMID: 26214649
-
Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis.Chest. 2012 Oct;142(4):1011-1019. doi: 10.1378/chest.11-2879. Chest. 2012. PMID: 22459774
-
[Bleomycin-induced pulmonary fibrosis following chemotherapy of ovarian granulosa cell tumor].Pneumologie. 1998 Jun;52(6):325-32. Pneumologie. 1998. PMID: 9715647 Review. German.
-
Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.Arch Ital Urol Androl. 2002 Jun;74(2):81-5. Arch Ital Urol Androl. 2002. PMID: 12161942 Review.
Cited by
-
Nintedanib treatment for bleomycin-induced lung injury - First report.Respir Med Case Rep. 2023 Sep 27;46:101921. doi: 10.1016/j.rmcr.2023.101921. eCollection 2023. Respir Med Case Rep. 2023. PMID: 37822763 Free PMC article.
-
Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report.Clin Case Rep. 2018 Sep 4;6(10):2011-2014. doi: 10.1002/ccr3.1790. eCollection 2018 Oct. Clin Case Rep. 2018. PMID: 30349718 Free PMC article.
-
Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.Cancers (Basel). 2025 Jul 30;17(15):2522. doi: 10.3390/cancers17152522. Cancers (Basel). 2025. PMID: 40805219 Free PMC article. Review.
-
Rituximab and Pirfenidone in the Treatment of Steroid-Refractory Bleomycin Lung Injury.Respirol Case Rep. 2025 Jul 14;13(7):e70228. doi: 10.1002/rcr2.70228. eCollection 2025 Jul. Respirol Case Rep. 2025. PMID: 40661338 Free PMC article.
References
-
- Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779–785. - PubMed
-
- Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408. doi: 10.1016/j.ejphar.2008.06.046. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources